CClinicalTrials.gg
Sign In
Status unknownNCT03754192PERCAHECUpdated Sep 1, 2020

Perfusion and Dual Energy Computer Tomography in Hepatocellular Carcinoma

An interventional study of perfusion Computed Tomography in Hepatocellular Carcinoma, sponsored by Assistance Publique - Hôpitaux de Paris. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-01.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Aug 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to evaluate the hepatic perfusion computer tomography and dual energy computer tomography in the assessment of tumor characterization of Hepatocellular carcinoma in patients with resectable Hepatocellular carcinoma by comparing the quantitative parameters computer tomography obtained with the pathological data of the surgical specimens.

Read the detailed description

Dual-energy computer tomography and perfusion computer tomography (General Electric revolution Hight definition Gemstone™ Spectral Imaging) will be performed in all patients. Iodine concentration and quantitative perfusion parameters of the Hepatocellular carcinoma and surrounding liver parenchyma data will be compared with the pathological results.

02

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Perfusion computer tomography
  • dual-energy computer tomography
03

In context

Carcinoma

6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.

This study's planned enrollment of 50 is above the median of 45 across 5,170 interventional studies indexed under Carcinoma.

Browse Carcinoma studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • A diagnosis of Hepatocellular carcinoma made according to the guidelines of the American Association for the study of the Liver
  • Affiliation to a national health insurance
  • An indication for hepatic resection during the decision-making stage
  • A request for a pre-operative Computer Tomography in our radiology unit
  • An affiliation to a social security
  • Informed consent given by the patient

Exclusion criteria

Exclusion Criteria:

  • Previous treatments of Hepatocellular carcinoma (medicated or surgical)
  • Patient under tutorship or curatorship
  • Pregnant or lactating woman
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    perfusion computed tomography

    Will be realsed before liver surgery

    Radiation: perfusion Computed Tomography

Interventions

  • Radiationperfusion Computed Tomography

    Will be carried before liver surgery

    Also known as: Computed tomography

06

What researchers measure

Primary outcomes

  1. Pefusion parameters

    correlation between pre-operative imaging data and histological data of Hepatocellular carcinoma

    Time frame: 5 minutes

Secondary outcomes

  1. Pathological examination

    Compare data obtained in perfusion computer tomography to the imaging data and to the Histological differentiation grades

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
  • CHU Paul Brousse
    Villejuif, 94800, France
    Recruiting
08

References and documents

Publications

  • Lewin M, Laurent-Bellue A, Desterke C, Radu A, Feghali JA, Farah J, Agostini H, Nault JC, Vibert E, Guettier C. Evaluation of perfusion CT and dual-energy CT for predicting microvascular invasion of hepatocellular carcinoma. Abdom Radiol (NY). 2022 Jun;47(6):2115-2127. doi: 10.1007/s00261-022-03511-7. Epub 2022 Apr 13. PubMed 35419748 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03754192
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Responsible party
Sponsor
First posted
Nov 27, 2018
Start date
Jan 30, 2019
Primary completion
Dec 30, 2020 (estimated)
Completion
Dec 30, 2020 (estimated)
Last update
Sep 1, 2020

Study contacts

LEWIN MAITE, MD, Phd
Contact
maite.lewin@aphp.fr
00 (33) 6 11 15 06 17
DA-MOTA-FERREIRA Jean-Manuel, Radiologic
Contact
jean-manuel.da-mota-ferreira@aphp.fr
00 (33) 145592474
LEWIN MAITE, MD, PhD
principal investigator · APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Carcinoma→

Other studies from this sponsor

Assistance Publique - Hôpitaux de Paris

Start the discussion